Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma  

Oleh:

Harousseau, Jean-Luc ; Moreau, Philippe

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 360 no. 25 (Jun. 2009), page 2645-2654.
Topik: Multiple myeloma

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2009.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Multiple myeloma is a malignant disorder in which plasma cells accumulate in the bone marrow and produce an entire immunoglobulin (usually IgG or IgA) or only immunoglobulin light chains (kappa or lambda).1 Multiple myeloma accounts for approximately 10% of hematologic cancers and 1% of all cancers. The annual incidence is 4 to 6 cases per 100,000 population. The American Cancer Society has estimated that more than 19,000 new cases were diagnosed in the United States in 2008. Multiple myeloma is primarily a disease of the elderly, with a median age range at diagnosis of 65 to 70 years. The disease does not occur in children. Common complications of multiple myeloma include osteolytic bone lesions, anemia, renal insufficiency, and infections. Signs and symptoms vary greatly, and the presentation may range from incidental abnormalities that are detected on routine blood screening to severe clinical manifestations, including paraplegia related to spinal cord compression. Multiple myeloma is frequently a painful and disabling disease because of bone involvement, which is a common feature. The prognosis for patients with multiple myeloma remains poor. The disease is uniformly fatal, with a median survival of approximately 3 years with conventional chemotherapy, although the outlook has improved somewhat with the advent of newer therapies during the past 10 years.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali